Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Technical Presentation (2025)
15 slides from Novo Nordisk A/s Class B's technical presentation, 2025
Slide 1: Comparative effectiveness of once-weekly semaglutide versus dulaglutide on cardiovascular outcomes
Comparative effectiveness of once-weekly semaglutide versus dulaglutide on cardiovascular outcomes in US Medicare beneficiaries with type 2 diabetes and atherosclerotic cardiovascular disease Xi Tan, PhD, PharmD1; Joanna Harton, PhD2; Yuanjie Liang, MS1; Lin Xie, MS1; Cynthia Gutierrez, MPH2; Chalak
Slide 2: Disclosures
01 02 Disclosures XT, YL, LX, CM, and JH and CG are CS are employees of employees of Genesis Novo Nordisk Inc. Research Group. 2
Slide 3: Background
Background 01 Semaglutide and dulaglutide reduce CV risk in T2D and ASCVD (trials + real-world evidence).1-3 Guidelines recommend GLP-1 receptor agonists (GLP-1 RAs) for managing T2D with 02 ASCVD or high-risk for ASCVD.4-5 Indirect comparisons demonstrated consistently lower CV risks for semaglutid
Slide 4: Objective
Objective To compare the risk of major adverse cardiovascular events (MACE) between those who initiated once-weekly (OW) semaglutide and dulaglutide among US individuals with T2D and ASCVD. 4 MACE: major adverse cardiovascular events; OW: once-weekly.
Slide 5: Methods: Study Design and Analyses
Methods: Study Design and Analyses Follow-up Period Baseline Period Patients were followed until earliest of death, outcome 1 year prior to the index date to assess occurrence, disenrollment, study end, index drug discontinuation, baseline characteristics or SGLT2i initiation (censored only if SGLT2
Slide 6: Methods: Outcome Measurement
Methods: Outcome Measurement + Stroke Definition 1 (ischemic and 3-point MI, all-cause death hemorrhagic) MACE Definition 2 Ischemic stroke + + Stroke (ischemic and Definition 1 hemorrhagic) 5-point MI, all-cause death, hospitalization for unstable angina, hospitalization for MACE heart failure Defi
Slide 7: Study Population
Study Population OW • Had confirmed T2D and • One-year continuous Excluded: Final sample ASCVD diagnoses enrolment at baseline • T1D, pregnancy, • Before matching semaglutide • New user of semaglutide • Evidence for ASCVD at contraindications N=29,170 • Aged ≥ 66 years as of baseline (N=59,667) • GL
Slide 8: Results: No significant differences in baseline characteristics after matching (SMD < 0.10)
Results: No significant differences in baseline characteristics after matching (SMD < 0.10) Before PS Matching After PS Matching Key Characteristics Semaglutide Dulaglutide Semaglutide Dulaglutide SMD SMD (n = 29,170) (n = 47,016) (n = 29,168) (n = 29,168) Age, mean (SD) 73.20 (5.24) 73.82 (5.70) 0.
Slide 9: Results: No significant differences in baseline characteristics after matching (SMD < 0.10)
Results: No significant differences in baseline characteristics after matching (SMD < 0.10) Before PS Matching After PS Matching Key Characteristics Semaglutide Dulaglutide Semaglutide Dulaglutide SMD SMD (n = 29,170) (n = 47,016) (n = 29,168) (n = 29,168) Type of ASCVD, n (%) • Ischemic stroke 1,11
Slide 10: Results: 3-point MACE
Results: 3-point MACE Dulaglutide N=29,168 Cumulative incidence curves OW semaglutide N=29,168 (Incidence rate [95% CI], per 1000 person-years) Hazard ratio (95% CI) Dulaglutide: Incidence rate (95% CI) Stroke 40.0 (37.8-42.3) 0.77 MI (0.71-0.84) All-cause death p <0.001 OW semaglutide: Incidence ra
Slide 11: Results: 5-point MACE
Results: 5-point MACE Dulaglutide N=29,168 Cumulative incidence curves OW semaglutide N=29,168 (Incidence rate [95% CI], per 1000 person-years) Hazard ratio (95% CI) Dulaglutide: Stroke, MI Incidence rate (95% CI) unstable angina, 47.1 (44.7-49.5) heart failure, 0.75 (0.70-0.82) all-cause death p <0
Slide 12: Results: Individual MACE events
Results: Individual MACE events Dulaglutide N=29,168 Cumulative incidence curves OW semaglutide N=29,168 (Incidence rate [95% CI], per 1000 person-years) Hazard ratio (95% CI) Dulaglutide: Incidence rate (95% CI) 10.0 (8.9-11.2) Stroke 0.67 (0.56-0.80) OW semaglutide: p <0.001 Incidence rate (95% CI
Slide 13: Results: Individual MACE events
Results: Individual MACE events Dulaglutide N=29,168 Cumulative incidence curves OW semaglutide N=29,168 (Incidence rate [95% CI], per 1000 person-years) Hazard ratio (95% CI) Dulaglutide: Incidence rate (95% CI) 9.6 (8.6-10.8) MI 0.90 (0.76-1.06) p = 0.21 OW semaglutide: Incidence rate (95% CI) 8.6
Slide 14: Discussion
Discussion Novel Comparative Study Study Study Evidence: Implication: Strengths: Limitations First real-world The established CV Representation of Observational study comparison of CV benefit of semaglutide Medicare, target trial design, data availability outcomes between OW is multifaceted, emulati
Slide 15: Conclusion
Among US Medicare beneficiaries with T2D and ASCVD, OW semaglutide was associated with reduced risks of CV outcomes, including a 01 23% risk reduction in 3-point MACE and a 26% risk reduction in all-cause death, compared to dulaglutide. Conclusion These findings address a critical evidence gap that